Compendium of polycystic ovarian syndrome and its relevance in glycation and diabetes

Abstract

Polycystic ovarian syndrome (PCOS) is one of the most common endocrine and reproductive disorders observed in women. Its pathophysiology indicates its involvement in plenitude of diseases and/ or disorders. Although the absolute cause of PCOS has not been established, its prevalence in diabetic patients is noteworthy. Glycation and insulin resistance being key factors in diabetes, the present review tries to study their correlation with PCOS. Amongst the available drugs, four commonly prescribed drugs namely, metformin, inositol, thiazolidinediones, and spironolactone have been discussed. The current review also provides insights about usage of M. oleifera and S. platensis as a potential therapeutic agent for symptomatic relief of PCOS.

Keywords

• Altered steroidogenesis
• Glycation
• Insulin resistance
• Insulin resistance
• PCOS
• Diabetes mellitus

References

1. 1. Nestler J. Insulin regulation of human ovarian androgens. Hum Reprod. 12(suppl 1), 1997; 53-62. DOI: 10.1093/humrep/12.suppl_1.53
2. 2. Schoemaker J. Neuroendocrine control in polycystic ovary-like syndrome. Gynec Endocrino. 1991; 5(4), 277-288. DOI: 10.3109/09513599109028449
3. 3. Diamanti-Kandarakis E & Piperi C. Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Hum Reprod Update. 2005; 11(6), 631-643. DOI: 10.1093/humupd/dmi025
4. 4. Xita N, Georgiou I, & Tsatsoulis A. The genetic basis of polycystic ovary syndrome. Eur J Endocrinol. 2002; 717-725. DOI: 10.1530/eje.0.1470717
5. 5. Diamanti-Kandarakis E & Dunaif A. Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and Implications. Endocrine Reviews. 2012; 33(6), 981-1030. DOI: 10.1210/er.2011-1034
6. 6. Diamanti-Kandarakis E & Dunaif A. PolyCystic Ovarian Syndrome: An Updated Overview. Front Physiol. 2012; 7, 124. https://doi.org/10.3389/fphys.2016.00124
7. 7. Bajuk Studen K & Pfeifer M. Cardiometabolic risk in polycystic ovary syndrome. Endocr Connect. 2018; 7(7), R238-R251. DOI: 10.1530/ec-18-0129
8. 8. Wang, F., Wang, S., Zhang, Z., Lin, Q., Liu, Y., & Xiao, Y. et al. Defective insulin signaling and the protective effects of dimethyldiguanide during follicular development in the ovaries of polycystic ovary syndrome. Mol Med Rep. 2017; 16(6), 8164-8170. DOI: 10.3892/mmr.2017.7678

9. 9. Dunaif A, Xia J, Book C, Schenker E & Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest. 1995; 96 (2), 801-810. DOI: 10.1172/jci118126
10. 10. Dunaif A, Segal K, Shelley D, Green G, Dobrjansky A & Licholai T. Evidence for distinctive and intrinsic defects in insulin action in Polycystic Ovary Syndrome. Diabetes. 1992; 41(10), 1257-1266. DOI: 10.2337/diab.41.10.1257
11. 11. Venkatesan A. Insulin Resistance in Polycystic Ovary Syndrome: Progress and Paradoxes. Recent Prog Horm Res. 2001; 56(1), 295-308. DOI: 10.1210/rp.56.1.295
12. 12. Sano H, Higashi T, Matsumoto K, Melkko J, Jinnouchi Y, & Ikeda K. et al. Insulin Enhances Macrophage Scavenger Receptor-mediated Endocytic Uptake of Advanced Glycation End Products. J Biol Chem. 1998; 273(15), 8630-8637. DOI: 10.1074/jbc.273.15.8630
13. 13. Diamanti-Kandarakis E, Piperi C, Kalofoutis A & Creatsas G. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol. 2005; 62(1), 37-43. DOI: 10.1111/j.1365-2265.2004.02170.x
14. 14. Ali A, Paramanya A, Prairna, Doukani K. Zehra S. Antioxidants in glycation related diseases. In Oxidative Stress and Antioxidant Defense: Biomedical Value in Health and Diseases, Md. Sahab Uddin and Aman Upaganlawar (Eds.). NOVA Science Publishers, Hauppauge, USA.2019. Pp. 465-488
15. 15. Ahmed N. Advanced glycation end products—role in pathology of diabetic complications. Diabetes Res Clin Pract. 2005; 67(1), 3-21. DOI: 10.1016/j.diabres.2004.09.004
16. 16. Draznin B. Molecular Mechanisms of Insulin Resistance: Serine Phosphorylation of Insulin Receptor Substrate-1 and Increased Expression of p85: The Two Sides of a Coin. Diabetes. 2006; 55(8), 2392-2397. DOI: 10.2337/db06-0391
17. 17. Ueki K, Algenstaedt P, Mauvais-Jarvis F, & Kahn C. Positive and Negative Regulation of Phosphoinositide 3-Kinase-Dependent Signaling Pathways by Three Different Gene Products of the p85α Regulatory Subunit. Mol Cell Biol. 2000; 20(21), 8035-8046. DOI: 10.1128/mcb.20.21.8035-8046.2000
18. 18. Terauchi Y, Tsuji Y, Satoh S, Minoura H, Murakami K, & Okuno A. et al. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85α subunit of phosphoinositide 3–kinase. Nat Genet. 1999; 21(2), 230-235. DOI: 10.1038/6023
19. 19. Giorgino F, Pedrini M, Matera L & Smith R. Specific Increase in p85α Expression in Response to Dexamethasone Is Associated with Inhibition of Insulin-like Growth Factor-I Stimulated Phosphatidylinositol 3-Kinase Activity in Cultured Muscle Cells. J Biol Chem. 1997; 272(11), 7455-7463. DOI: 10.1074/jbc.272.11.7455
20. 20. Cornier M, Bessesen D, Gurevich I, Leitner J & Draznin B. Nutritional upregulation of p85α expression is an early molecular manifestation of insulin resistance. Diabetologia. 2006; 49(4), 748-754. DOI: 10.1007/s00125-006-0148-0
21. 21. Bandyopadhyay G, Yu J, Ofrecio J & Olefsky J. Increased p85/55/50 Expression and Decreased Phosphatidylinositol 3-Kinase Activity in Insulin-Resistant Human Skeletal Muscle. Diabetes. 2005; 54(8), 2351-2359. DOI: 10.2337/diabetes.54.8.2351
22. 22. Saini V. Molecular mechanisms of insulin resistance in type 2 diabetes mellitus. World J Diabetes. 2010; 1(3):68-75. DOI:10.4239/wjd.v1.i3.68
23. 23. Qiao LY, Goldberg JL, Russell JC & Sun XJ. Identification of enhanced serine kinase activity in insulin resistance. J Biol Chem. 1999; 274(15), 10625-10632. DOI: 10.1074/jbc.274.15.10625
24. 24. Samuel V, & Shulman G. Mechanisms for Insulin Resistance: Common Threads and Missing Links. Cell. 2012; 148(5), 852-871. DOI: 10.1016/j.cell.2012.02.017
25. 25. Samuel V, Petersen K & Shulman G. Lipid-induced insulin resistance: unravelling the mechanism. The Lancet. 2010; 375(9733), 2267-2277. DOI: 10.1016/s0140-6736(10)60408-4
26. 26. Itani S, Ruderman N, Schmieder F & Boden, G. Lipid-Induced Insulin Resistance in Human Muscle Is Associated With Changes in Diacylglycerol, Protein Kinase C, and I B-. Diabetes. 2002; 51(7), 2005-2011. DOI: 10.2337/diabetes.51.7.2005
27. 27. Garvey WT, Maianu L, Zhu JH, Brechtel-Hook G, Wallace P & Baron AD. Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance. J Clin Invest. 1998; 101(11), 2377–2386. https://doi.org/10.1172/JCI1557
28. 28. Fabbrini E, Magkos F, Mohammed B, Pietka T, Abumrad N & Patterson B. et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA. 2009 106(36), 15430-15435. DOI: 10.1073/pnas.0904944106
29. 29. Kaufman R. Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev. 1999; 13(10), 1211-1233. DOI: 10.1101/gad.13.10.1211
30. 30. Dresner A, Laurent D, Marcucci M, Griffin M, Dufour S & Cline G. et al. Effects of free fatty acids on glucose transport and IRS-1–associated phosphatidylinositol 3-kinase activity. J Clin Invest. 1999; 103(2), 253-259. DOI: 10.1172/jci5001
31. 31. Kumar D, Ali A. 2019. Antiglycation and Antiaggregation potential of Thymoquinine. Nat Volat Essent Oils. 6 (1): 25-33
32. 32. Hodge J. Dehydrated Foods, Chemistry of Browning Reactions in Model Systems. J Agric Food Chem. 1953; 1(15), 928-943. DOI: 10.1021/jf60015a004
33. 33. Paul R & Bailey A. Glycation of collagen: the basis of its central role in the late complications of ageing and diabetes. Int J Biochem Cell Biol. 1996; 28(12), 1297-1310. DOI: 10.1016/s1357-2725(96)00079-9
34. 34. Thorpe S & Baynes J. Maillard reaction products in tissue proteins: New products and new perspectives. Amino Acids. 2003; 25(3-4), 275-281. DOI: 10.1007/s00726-003-0017-9
35. 35. Ali A, More T, Hoonjan A K, Sivakami S. 2017. Antiglycating potential of Acesulfame potassium: An artificial sweetener. App Physiol Nutr Metabol. 2017. 42(10):1054-1063. http://dx.doi.org/10.1139/apnm-2017-0119.
36. 36. Reddy S, Bichler J, Wells-Knecht K, Thorpe S & Baynes J. N.epsilon.-(Carboxymethyl)lysine Is a Dominant Advanced Glycation End Product (AGE) Antigen in Tissue Proteins. Biochem. 1995; 34(34), 10872-10878. DOI: 10.1021/bi00034a021
37. 37. Negre-Salvayre A, Coatrieux C, Ingueneau C & Salvayre R. Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors. Br J Pharmacol. 2008; 153(1), 6-20. DOI: 10.1038/sj.bjp.0707395
38. 38. Moldogazieva N, Mokhosoev I, Mel’nikova T, Porozov Y & Terentiev A. Oxidative Stress and Advanced Lipoxidation and Glycation End Products (ALEs and AGEs) in Aging and Age-Related Diseases. Oxid Med Cell Longev. 2019; 1-14. DOI: 10.1155/2019/3085756
39. 39. Kim J & Choi Y. Dyslipidemia in women with polycystic ovary syndrome. Obstet Gynecol Sci. 2013; 56(3), 137. DOI: 10.5468/ogs.2013.56.3.137
40. 40. Rutkowska A & Diamanti-Kandarakis E. (2016). Do Advanced Glycation End Products (AGEs) Contribute to the Comorbidities of Polycystic Ovary Syndrome (PCOS)?. Curr Pharm Des. 2016; 22(36), 5558-5571. DOI: 10.2174/1381612822666160714094404
41. 41. Gkogkolou P & Böhm M. (2012). Advanced glycation end products: Key players in skin aging? Dermatoendocrinol. 2012; 4(3), 259–270. https://doi.org/10.4161/derm.22028
42. 42. Miyata T, Inagi R, Iida Y, Sato M, Yamada N & Oda O. et al. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. J Clin Invest. 1994; 93(2), 521-528. DOI: 10.1172/jci117002
43. 43. Bierhaus A, Humpert P, Morcos M, Wendt T, Chavakis T & Arnold B. et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med. 2005; 83(11), 876-886. DOI: 10.1007/s00109-005-0688-7
44. 44. Xue M, Rabbani N, & Thornalley P. Glyoxalase in ageing. Semin Cell Dev Biol. 2011; 22(3), 293-301. DOI: 10.1016/j.semcdb.2011.02.013
45. 45. Chen L, Chen R, Wang H & Liang F. Mechanisms Linking Inflammation to Insulin Resistance. Int J Endocrinol. 2015; 1-9. DOI: 10.1155/2015/508409
46. 46. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, & Yamamoto H. (2000). The Receptor for Advanced Glycation End Products Is Induced by the Glycation Products Themselves and Tumor Necrosis Factor-α through Nuclear Factor-κB, and by 17β-Estradiol through Sp-1 in Human Vascular Endothelial Cells. J Biol Chem, 275(33), 25781-25790. DOI: 10.1074/jbc.m001235200
47. 47. Diamanti-Kandarakis E & Papavassiliou A. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med. 2006; 12(7), 324-332. DOI: 10.1016/j.molmed.2006.05.006
48. 48. Baptiste, C., Battista, M., Trottier, A., & Baillargeon, J. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2010; 122(1-3), 42-52. doi: 10.1016/j.jsbmb.2009.12.010
49. 49. Schoemaker J. Neuroendocrine control in polycystic ovary-like syndrome. Gynecol Endocrinol. 1991; 5(4), 277-288. DOI: 10.3109/09513599109028449
50. 50. Fauser B, Tarlatzis B, Rebar R, Legro R, Balen A & Lobo R. et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012; 97(1), 28-38.e25. DOI: 10.1016/j.fertnstert.2011.09.024
51. 51. Kirschner M & Wayne Bardin C. Androgen production and metabolism in normal and virilized women. Metabolism. 1972; 21(7), 667-688. DOI: 10.1016/0026-0495(72)90090-x
52. 52. Balen A. The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology. Best Pract Res Clin Obstet Gynaecol. 2004; 18(5), 685-706. DOI: 10.1016/j.bpobgyn.2004.05.004
53. 53. Zhang LH, Rodriguez H, Ohno S & Miller WL. Serine phosphorylation of human P450c17 increases 17, 20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc Natl Acad Sci USA. 1995; 92: 10619–10623. https://dx.doi.org/10.1073%2Fpnas.92.23.10619
54. 54. White D, Leigh A, Wilson C, Donaldson A & Franks S. Gonadotropin and gonadal steroid response to a single dose of a long-acting agonist of gonadotropin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome. Clin Endocrinol. 1995; 42(5), 475-481. DOI: 10.1111/j.1365-2265.1995.tb02665.x
55. 55. Sıklar Z, Berberoğlu M, Çamtosun E, & Kocaay P. Diagnostic Characteristics and Metabolic Risk Factors of Cases with Polycystic Ovary Syndrome during Adolescence. J Pediatr Adolesc Gynecol. 2015; 28(2), 78-83. DOI: 10.1016/j.jpag.2014.05.006
56. 56. Baillargeon J, Iuorno M & Nestler J. Insulin Sensitizers for Polycystic Ovary Syndrome. Clin Obstet Gynecol. 2003; 46(2), 325-340. DOI: 10.1097/00003081-200306000-00011
57. 57. Dunaif A. Hyperandrogenic anovulation (PCOS): A unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus. Am J Med. 1995; 98(1), S33-S39. DOI: 10.1016/s0002-9343(99)80057-6
58. 58. Rathsman B, Rosfors S, Sjöholm Å & Nyström T. Early signs of atherosclerosis are associated with insulin resistance in non-obese adolescent and young adults with type 1 diabetes. Cardiovasc Diabetol. 2012; 11(1), 145. DOI: 10.1186/1475-2840-11-145
59. 59. Bhattacharya S & Jha A. Prevalence and risk of metabolic syndrome in adolescent Indian girls with polycystic ovary syndrome using the 2009 ‘joint interim criteria’. J Obstet Gynaecol Res. 2011; 37(10), 1303-1307. DOI: 10.1111/j.1447-0756.2010.01516.x
60. 60. Hart R, Doherty D, Mori T, Huang R, Norman R & Franks S. et al. Extent of metabolic risk in adolescent girls with features of polycystic ovary syndrome. Fertil Steril. 2011; 95(7), 2347-2353.e1. DOI: 10.1016/j.fertnstert.2011.03.001
61. 61. Lass N, Kleber M, Winkel K, Wunsch R & Reinehr T. Effect of Lifestyle Intervention on Features of Polycystic Ovarian Syndrome, Metabolic Syndrome, and Intima-Media Thickness in Obese Adolescent Girls. J Clin Endocrinol Metab. 2011; 96(11), 3533-3540. DOI: 10.1210/jc.2011-1609
62. 62. Garg D, Merhi Z. Relationship between Advanced Glycation End Products and Steroidogenesis in PCOS. Reprod Biol Endocrinol. 2016; 14(1):71. Published 2016 Oct 21. DOI:10.1186/s12958-016-0205-6
63. 63. Chatzigeorgiou A, Kandaraki E, Piperi C, Livadas S, Papavassiliou A & Koutsilieris, M. et al. Dietary glycotoxins affect scavenger receptor expression and the hormonal profile of female rats. J Endocrinol. 2013; 218(3), 331-337. DOI: 10.1530/joe-13-0175
64. 64. Franks S. Polycystic Ovary Syndrome. N Engl J Med. 1995; 333(13), 853-861. DOI: 10.1056/nejm199509283331307
65. 65. Rabbani N & Thornalley P. Dicarbonyl stress in cell and tissue dysfunction contributing to ageing and disease. Biochem Biophys Res Commun. 2015; 458(2), 221-226. DOI: 10.1016/j.bbrc.2015.01.140
66. 66. Zhao Z, Zhao C, Zhang X, Zheng F, Cai W, Vlassara H, & Ma Z. Advanced Glycation End Products Inhibit Glucose-Stimulated Insulin Secretion through Nitric Oxide-Dependent Inhibition of Cytochrome c Oxidase and Adenosine Triphosphate Synthesis. Endocrinol. 2009; 150(6), 2569-2576. DOI: 10.1210/en.2008-1342
67. 67. Ollila M, Piltonen T, Puukka K, Ruokonen A, Järvelin M & Tapanainen J. et al. Weight Gain and Dyslipidemia in Early Adulthood Associate with Polycystic Ovary Syndrome: Prospective Cohort Study. J Clin Endocrinol Metab. 2016; 101(2), 739-747. DOI: 10.1210/jc.2015-3543
68. 68. Morgan C, Jenkins-Jones S, Currie C & Rees D. Evaluation of Adverse Outcome in Young Women with Polycystic Ovary Syndrome Versus Matched, Reference Controls: A Retrospective, Observational Study. J Clin Endocrinol Metab. 2012; 97(9), 3251-3260. DOI: 10.1210/jc.2012-1690
69. 69. Joham A, Ranasinha S, Zoungas S, Moran L & Teede H. Gestational Diabetes and Type 2 Diabetes in Reproductive-Aged Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2014; 99(3), E447-E452. DOI: 10.1210/jc.2013-2007
70. 70. Moran L, Misso M, Wild R & Norman R. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010; 16(4), 347-363. DOI: 10.1093/humupd/dmq001
71. 71. Legro R, Kunselman A, Dodson W & Dunaif A. Prevalence and Predictors of Risk for Type 2 Diabetes Mellitus and Impaired Glucose Tolerance in Polycystic Ovary Syndrome: A Prospective, Controlled Study in 254 Affected Women1. J Clin Endocrinol Metab. 1999; 84(1), 165-169. DOI: 10.1210/jcem.84.1.5393
72. 72. Norman R, Masters L, Milner C, Wang J, & Davies M. Relative risk of conversion from normoglycemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod. 2001; 16(9), 1995-1998. DOI: 10.1093/humrep/16.9.1995
73. 73. Wang E, Calderon-Margalit R, Cedars M, Daviglus M, Merkin S & Schreiner P. et al. Polycystic Ovary Syndrome and Risk for Long-Term Diabetes and Dyslipidemia. Obstet Gynecol. 2011; 117(1), 6-13. DOI: 10.1097/aog.0b013e31820209bb
74. 74. Baillargeon JP, Nestler JE, Ostlund RE, Apridonidze T, Diamanti-Kandarakis E. Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism. Hum Reprod. 2008; 23, 1439–1446. 10.1093/humrep/den097
75. 75. Lungu AO, Zadeh ES, Goodling A, Cochran E, Gorden P. Insulin resistance is a sufficient basis for hyperandrogenism in lipodystrophic women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2012; 97, 563–567. 10.1210/jc.2011-1896
76. 76. Kalme T, Koistinen H, Loukovaara M, Koistinen R, Leinonen P. Comparative studies on the regulation of insulin-like growth factor-binding protein-1 (IGFBP-1) and sex hormone-binding globulin (SHBG) production by insulin and insulin-like growth factors in human hepatoma cells. J Steroid Biochem Mol Biol. 2003; 86, 197–200. 10.1016/S0960-0760(03)00268-1
77. 77. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv. 2004; 59, 141–154. 10.1097/01.OGX.0000109523.25076.E2
78. 78. Nawrocka-Rutkowska J, Ciecwiez S, Marciniak A, Brodowska A, Wisniewska B, Kotlega D, et al. Insulin resistance assessment in patients with polycystic ovary syndrome using different diagnostic criteria–impact of metformin treatment. Ann Agric Environ Med. 2013; 20, 528–532.
79. 79. Misso M, Boyle J, Norman R, Teede H. Development of evidenced-based guidelines for PCOS and implications for community health. Semin Reprod Med. 2014; 32, 230–240. 10.1055/s-0034-1371095
80. 80. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013; 98, 4565–4592. 10.1210/jc.2013-2350
81. 81. Teede HJ, Misso ML, Deeks AA, Moran LJ, Stuckey BG, Wong JL, et al. Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. Med J Aust. 2011; 195, S65–S112. 10.5694/mja11.10915
82. 82. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. The Lancet 2007; 370, 685–697. 10.1016/S0140-6736(07)61345-2
83. 83. Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG. 2006; 113, 1148–1159. 10.1111/j.1471-0528.2006.00990.x
84. 84. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346, 393–403. 10.1056/NEJMoa012512
85. 85. Clark AM, Thornley B, Tomlinson L, Galletley C, Norman RJ. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod. 1998; 13, 1502–1505. 10.1093/humrep/13.6.1502
86. 86. Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. 2007; Cochrane Database Syst Rev 1: CD005552.
87. 87. Yildiz BO. Approach to the patient: contraception in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2015; 100, 794–802. 10.1210/jc.2014-3196
88. 88. Yildiz BO. Oral contraceptives in polycystic ovary syndrome: risk-benefit assessment. Semin Reprod Med. 2008b; 26, 111–120. 10.1055/s-2007-992931
89. 89. El Hayek S, Bitar L, Hamdar LH, Mirza FG, & Daoud G. PolyCystic Ovarian Syndrome: An Updated Overview. Front Physiol. 2016; 7, 124. doi:10.3389/fphys.2016.00124
90. 90. Spritzer PM, Motta AB, Sir-Petermann T, Diamanti-Kandarakis E. Novel strategies in the management of polycystic ovary syndrome. Minerva Endocrinol. 2015; 40, 195–212.
91. 91. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen HK. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril. 1998; 69, 691–696. 10.1016/S0015-0282(98)00011-9
92. 92. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574–579
93. 93. Gilani A, Bashir S, Janbaz K & Shah A. Presence of cholinergic and calcium channel blocking activities explains the traditional use of Hibiscus rosasinensis in constipation and diarrhoea. J Ethnopharmacol. 2005; 102(2), 289-294. DOI: 10.1016/j.jep.2005.07.023
94. 94. Gopalakrishnan L, Doriya K & Kumar D. Moringa oleifera: A review on nutritive importance and its medicinal application. Food Sci Human Wellness, 2016; 5(2), 49-56. DOI: 10.1016/j.fshw.2016.04.001
95. 95. Wang Z, Zhai D, Zhang D, Bai L, Yao R & Yu J. et al. Quercetin Decreases Insulin Resistance in a Polycystic Ovary Syndrome Rat Model by Improving Inflammatory Microenvironment. Reprod Sci. 2016; 24(5), 682-690. DOI: 10.1177/1933719116667218
96. 96. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574–579
97. 97. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 1994; 43, 647–654. 10.1016/0026-0495(94)90209-7
98. 98. Pau CT, Keefe C, Duran J, Welt CK. Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study. J Clin Endocrinol Metab. 2014; 99, 1870–1878. 10.1210/jc.2013-4021
99. 99. Misitzis A, Cunha PR, Kroumpouzos G. Skin disease related to metabolic syndrome in women. Int J Womens Dermatol. 2019 Jul 4;5(4):205-212. eCollection 2019 Sep. Review. PubMed PMID: 31700973.
100. 100. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997; 82, 524–530. 10.1210/jc.82.2.524
101. 101. Koivunen RM, Morin-Papunen LC, Ruokonen A, Tapanainen JS, Martikainen HK. Ovarian steroidogenic response to human chorionic gonadotrophin in obese women with polycystic ovary syndrome: effect of metformin. Hum Reprod. 2001 Dec;16(12):2546-51. doi: 10.1093/humrep/16.12.2546. PMID: 11726572.
102. 102. Açbay O, Gündoğdu S. Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Steril. 1996; 65, 946–949.
103. 103. Huang Y, Sun J, Wang X, Tao X, Wang H, & Tan, W. Asymptomatic chronic gastritis decreases metformin tolerance in patients with type 2 diabetes. J Clinic Pharm Therapeutics, 2015; 40(4), 461-465.
104. 104. Soeprijanto B, Assegaf JH. Mekanisme peningka-tan heat shock protein-70 PADA kanker payudara tikus yang diradiasi, pascapemberian ekstrak meniran (phyllanthusniruri)(mechanism of increasing of Hsp-70 on irradiated rat breast cancer, due to application of extract of phyllanthus nir. J Vet. 2014; 15(3), 330-336
105. 105. Lashen H. (2010). Role of metformin in the management of polycystic ovary syndrome. Therapeut Adv Endocrinol Metabol. 2010; 1(3), 117-128.
106. 106. Majuri A, Santaniemi M, Rautio K, Kunnari A, Vartiainen J, Ruokonen A, et al. Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. Eur J Endocrinol. 156, 263–269. 2007; 10.1530/eje.1.02331
107. 107. Lee EJ, Marcy TR. The impact of pioglitazone on bladder cancer and cardiovascular events. Consult Pharm. 2014; 29, 555–558. 10.4140/TCP.n.2014.555
108. 108. Levin D, Bell S, Sund R, Hartikainen SA, Tuomilehto J, Pukkala E, et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia. 2015; 58, 493–504. 10.1007/s00125-014-3456-9
109. 109. Genazzani AD, Prati A, Santagni S, Ricchieri F, Chierchia E, Rattighieri E, et al. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecol Endocrinol. 2012; 28, 969–973. 10.3109/09513590.2012.685205
110. 110. Morgante G, Cappelli V, Di Sabatino A, Massaro MG, De Leo V. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association. Minerva Ginecol. 2015; 67, 457–463.
111. 111. Papaleo E, Unfer V, Baillargeon JP, Fusi F, Occhi F, De Santis L. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril. 2009; 91, 1750–1754. 10.1016/j.fertnstert.2008.01.088
112. 112. Sortino MA, Salomone S, Carruba MO, Drago F. Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols. Front Pharmacol. 2017;8:341. Published 2017 Jun 8. doi:10.3389/fphar.2017.00341
113. 113. Rago R, Marcucci I, Leto G, Caponecchia L, Salacone P, Bonanni P, et al. Effect of myo-inositol and alpha-lipoic acid on oocyte quality in polycystic ovary syndrome non-obese women undergoing in vitro fertilization: a pilot study. J Biol Regul Homeost Agents 2015; 29, 913–923.
114. 114. Nordio M, Proietti E. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci. 2012; 16, 575–581.
115. 115. Ganie MA, Khurana ML, Eunice M, Gupta N, Gulati M, Dwivedi SN, et al. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. J Clin Endocrinol Metab.2004; 89, 2756–2762. 10.1210/jc.2003-031780
116. 116. Ganie M, Khurana M, Nisar S, Shah P, Shah Z, Kulshrestha B et al. Improved Efficacy of Low-Dose Spironolactone and Metformin Combination Than Either Drug Alone in the Management of Women With Polycystic Ovary Syndrome (PCOS): A Six-Month, Open-Label Randomized Study. J Clin Endocrinol Metab. 2013;98(9):3599-3607.
117. 117. Zulian E, Sartorato P, Benedini S, Baro G, Armanini D, Mantero F et al. Spironolactone in the treatment of polycystic ovary syndrome: Effects on clinical features, insulin sensitivity and lipid profile. J Endocrinolo Invest. 2005;28(3):49-53.
118. 118. Cedars MI. Polycystic ovary syndrome: what is it and how should we treat it? J Pediatr. 2004; 144, 4–6. 10.1016/j.jpeds.2003.10.032
119. 119. Pfeifer SM, Dayal M. Treatment of the adolescent patient with polycystic ovary syndrome. Obstet Gynecol Clin North Am. 2003; 30, 337–352. 10.1016/S0889-8545(03)00028-7
120. 120. Gilani A, Bashir S, Janbaz K & Shah A. Presence of cholinergic and calcium channel blocking activities explains the traditional use of Hibiscus rosasinensis in constipation and diarrhoea. J Ethnopharmacol. 2005; 102(2), 289-294. DOI: 10.1016/j.jep.2005.07.023
121. 121. Gopalakrishnan L, Doriya K & Kumar D. Moringa oleifera: A review on nutritive importance and its medicinal application. Food Sci Human Wellness, 2016; 5(2), 49-56. DOI: 10.1016/j.fshw.2016.04.001
122. 122. Wang Z, Zhai D, Zhang D, Bai L, Yao R & Yu J. et al. Quercetin Decreases Insulin Resistance in a Polycystic Ovary Syndrome Rat Model by Improving Inflammatory Microenvironment. Reprod Sci. 2106; 24(5), 682-690. DOI: 10.1177/1933719116667218
123. 123. Juźwiak S, Wójcicki J, Mokrzycki K, et al. Effect of quercetin on experimental hyperlipidemia and atherosclerosis in rabbits. Pharmacol Rep. 2005; 57(5):604-609. https://pubmed.ncbi.nlm.nih.gov/16227643/
124. 124. Zhai H, Wu H, Xu H, Weng P, Xia F, Chen Y & Lu, Y. Trace glucose and lipid metabolism in high androgen and high-fat diet induced polycystic ovary syndrome rats. Reprod Biol Endocrinol. 2012; 10(1), 5. DOI: 10.1186/1477-7827-10-5
125. 125. Shah K & Patel S. (2015). Phosphatidylinositide 3-kinase inhibition: A new potential target for the treatment of polycystic ovarian syndrome. Pharmaceut Biol. 2015; 54(6), 975-983. DOI: 10.3109/13880209.2015.1091482
126. 126. Volpi E, Lieberman S, Ferrer D, Gilkison C, Rasmussen B, Nagamani M & Urban R. The Relationships Between Testosterone, Body Composition, and Insulin Resistance: A lesson from a case of extreme hyperandrogenism. Diabetes Care. 2005; 28(2), 429-432. DOI: 10.2337/diacare.28.2.429
127. 127. Amelia D, Santoso B, Purwanto B, Miftahussurur M, Joewono H & Budiono. Effects of Moringa oleifera on Insulin Levels and Folliculogenesis in Polycystic Ovary Syndrome Model with Insulin Resistance. Immunol Endocr Metab Agents Med Chem. 2018; 18(1), 22-30. DOI: 10.2174/1871522218666180426100754
128. 128. Paramanya A, Jha P, Ali A. 2019. Bioactive compounds in Spirulina sp.: Applications and potential health effects. In Next Generation research in Aquaculture, J K Sundaray and M A Rather (Eds.) Narendra Publishing House, Delhi. Pp. 197-218.
129. 129. Sotiroudis T & Sotiroudis G. Health aspects of Spirulina (Arthrospira) microalga food supplement. J Serb Chem Soc. 2013; 78(3), 395-405. DOI: 10.2298/jsc121020152s
130. 130. Wan D, Wu Q & Kuča K. Spirulina. Nutraceuticals. 2016; 569-583. DOI: 10.1016/b978-0-12-802147-7.00042-5
131. 131. Deng R & Chow T. Hypolipidemic, Antioxidant, and Antiinflammatory Activities of Microalgae Spirulina. Cardiovascular Therapeutics. 2010; 28(4), e33-e45. DOI: 10.1111/j.1755-5922.2010.00200.x
132. 132. Kato T, Takemoto K, Katayama H & Kuwabara Y. Eiyo To Shokuryo. 1984; 37(4), 323-332. DOI: 10.4327/jsnfs.37.323
133. 133. Blé-Castillo J, Rodrıguez-Hernández A, Miranda-Zamora R, Juárez-Oropza, M & Dıaz-Zagoya J. Arthrospira maxima prevents the acute fatty liver induced by the administration of simvastatin, ethanol and a hypercholesterolemic diet to mice. Life Sci. 2002; 70(22), 2665-2673. DOI: 10.1016/s0024-3205(02)01512-6
134. 134. Mani U, Desai S & Iyer U. Studies on the Long-Term Effect of Spirulina Supplementation on Serum Lipid Profile and Glycated Proteins in NIDDM Patients. J Nutraceut Funct Med Food. 2000; 2(3), 25-32. DOI: 10.1300/j133v02n03_03
135. 135. Parikh P, Mani U & Iyer U. Role of Spirulina in the Control of Glycemia and Lipidemia in Type 2 Diabetes Mellitus. J Med Food. 2001; 4(4), 193-199. DOI: 10.1089/10966200152744463
136. 136. Lee E, Park J, Choi Y, Huh K & Kim W. A randomized study to establish the effects of spirulina in type 2 diabetes mellitus patients. Nutri Res Practice. 2008; 2(4), 295. DOI: 10.4162/nrp.2008.2.4.295
137. 137. Kaur K, Sachdeva R & Grover K. Effect of supplementation of Spirulina on blood glucose and lipid profile of the non-insulin dependent diabetic male subjects. J Dairying, Foods Home Sci. 2008; 27(3and4), 202-208.
138. 138. Samuels R, Mani U, Iyer U & Nayak U. Hypocholesterolemic Effect ofSpirulinain Patients with Hyperlipidemic Nephrotic Syndrome. J Med Food. 2002; 5(2), 91-96. DOI: 10.1089/109662002760178177
139. 139. Mazokopakis E, Karefilakis C, Tsartsalis A, Milkas A & Ganotakis E. Acute rhabdomyolysis caused by Spirulina (Arthrospira platensis). Phytomedicine. 2008; 15(6-7), 525-527. DOI: 10.1016/j.phymed.2008.03.003
140. 140. Ali A & Paramanya A. Antidiabetic and Antiglycating properties of Spirulina platensis. 2019; MESMAP–5 PROCEEDINGS BOOK, 79.
141. 141. Shaikh N, Dadachanji R & Mukherjee S. Genetic Markers of Polycystic Ovary Syndrome: Emphasis on Insulin Resistance. Intl J Med Genetics. 2014; 1-10. DOI: 10.1155/2014/478972